Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.267
Sell
RSI(14)
38.521
Neutral
STOCH(KDJ)(9,3,3)
44.027
Neutral
ATR(14)
1.723
Low Volatility
CCI(14)
-50.690
Neutral
Williams %R
63.798
Sell
TRIX(12,20)
-0.298
Sell
StochRSI(14)
0.000
Sell
Utah Medical Products Inc
UTMD57.880USD
-0.120-0.21%
Close 11/06, 16:00（ET）Quotes delayed by 15 min
186.14MMarket Cap
14.83P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Utah Medical Products Inc
Currency: USD Updated: 2025-11-06Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Utah Medical Products Inc's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Utah Medical Products Inc Highlights
StrengthsRisks
Utah Medical Products, Inc. is engaged in the business of producing medical services. The Company markets a range of medical devices used in critical care areas, especially the neonatal intensive care unit (NICU), the labor and delivery (L&D) department and the women's health center in hospitals, as well as medical devices sold to outpatient clinics and physician's offices. Its products include BT-CATH, CVX-RIPE, AROM-COT, MUC-X, CORDGUARD, DISPOSA-HOOD, DELTRAN PLUS, GESCO, PICC-NATE, LETZ System, Filshie Clip System, PATHFINDER PLUS, SUPRAPUBIC CATHETERIZATION, LIBERTY System, ENDOCURETTE, LUMIN, and BioPharm HP-PRT, among others. BT-CATH is a uterine balloon tamponade catheter for controlling severe postpartum hemorrhage. MUC-X is an aspiration device used immediately after birth to clear neonatal respiratory passages and reduce exposure to potential infections. AROM-CO is a finger cover with a prong designed to rupture maternal membranes with less patient pain and anxiety.
Growing
The company is in a growing phase, with the latest annual income totaling USD 40.90M.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 30.19%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 30.19%.
Fairly Valued
The company’s latest PE is 15.44, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.28M shares, decreasing 23.18% quarter-over-quarter.
Held by Brandes Investmen
Star Investor Brandes Investmen holds 333.20K shares of this stock.
Financial Health
Currency: USD Updated: 2025-11-06The company's current financial score is 9.52, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 9.95M, representing a year-over-year decrease of 4.30%, while its net profit experienced a year-over-year decrease of 11.73%.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
8.47
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
9.13
Utah Medical Products Inc's Company Valuation
Currency: USD Updated: 2025-11-06The company’s current valuation score is 8.45, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is 15.44, which is 43.40% below the recent high of 22.14 and 11.49% above the recent low of 13.67.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 110/210
No Data
Earnings Forecast
Currency: USD Updated: 2025-11-06There is no earnings forecast score for this company; the Healthcare Equipment & Supplies industry's average is 7.74.
Score
Support & Resistance
No Data
No Data
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-11-06The company’s current price momentum score is 6.58, which is lower than the Healthcare Equipment & Supplies industry's average of 6.74. Sideways: Currently, the stock price is trading between the resistance level at 62.28 and the support level at 54.57, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
58.144
Sell
MA10
58.253
Sell
MA20
59.361
Sell
MA50
61.354
Sell
MA100
59.151
Sell
MA200
57.908
Sell
Institutional Confidence
Currency: USD Updated: 2025-11-06The company’s current institutional recognition score is 7.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.40. The latest institutional shareholding proportion is 71.16%, representing a quarter-over-quarter decrease of 8.52%. The largest institutional shareholder is Brandes Investmen, holding a total of 333.20K shares, representing 10.39% of shares outstanding, with 116.32% increase in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
Dimensional Fund Advisors, L.P.
Cornwell (Kevin L)
BlackRock Institutional Trust Company, N.A.
Geode Capital Management, L.L.C.
Minerva Advisors LLC
State Street Investment Management (US)
1
2
Risk Assessment
Currency: USD Updated: 2025-11-06The company’s current risk assessment score is 5.15, which is higher than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.33. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.33
VaR
+2.44%
240-Day Maximum Drawdown
+21.56%
240-Day Volatility
+28.40%
Return
Best Daily Return
60 days
+6.01%
120 days
+6.01%
5 years
+14.60%
Worst Daily Return
60 days
-4.26%
120 days
-4.26%
5 years
-11.13%
Sharpe Ratio
60 days
+0.21
120 days
+0.57
5 years
-0.07
Risk Assessment
Maximum Drawdown
240 days
+21.56%
3 years
+48.52%
5 years
+57.74%
Return-to-Drawdown Ratio
240 days
-0.46
3 years
-0.27
5 years
-0.11
Skewness
240 days
+0.46
3 years
-0.23
5 years
+0.50
Volatility
Realised Volatility
240 days
+28.40%
5 years
+32.96%
Standardised True Range
240 days
+2.31%
5 years
+3.78%
Downside Risk-Adjusted Return
120 days
+99.84%
240 days
+99.84%
Maximum Daily Upside Volatility
60 days
+24.36%
Maximum Daily Downside Volatility
60 days
+25.68%
Liquidity
Average Turnover Rate
60 days
+0.50%
120 days
+0.49%
5 years
--
Turnover Deviation
20 days
-21.93%
60 days
-9.51%
120 days
-10.52%
Peer Comparison
Healthcare Equipment & Supplies
Utah Medical Products Inc
UTMD
6.18 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
CSTL
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
COR
8.64 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AXGN
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
AORT
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
